Alain Coudray joins Gondola’s Board of Directors
Gondola Medical Technologies is excited to announce that Alain Coudray has joined the board of directors. As the company is heading towards many exciting milestones, including a market entry in Germany and the USA, Alain Coudray’s knowledge and experience will be of significant value.
Learn more about Alain Coudray and his experience in the MedTech industry in the following interview:
Could you introduce yourself in a few words?
I am a passionate and innovative business professional with 20+ years of experience in MedTech companies’ management. Previously, I held the position of Vice President-Global Corporate Clinical Affairs at Medtronic and Vice President-Central & Eastern Europe Region at Guidant. I started as a medical student but then continued with business studies instead. From there on forward, I created a biotech start-up, a multi-media communications company. Then, I entered the medical industry by joining a company that Boston and Abbott later bought. Throughout the years, I continuously evolved until I decided to retire from active corporate roles to support promising start-ups in 2017.
What motivates you as an individual?
Something that motivates me on a day-to-day basis is contributing to our society. One might say that this sounds idealistic, but the desire to have a positive impact on society is something that has been continuous guidance throughout my career. I have also always been passionate about pushing human capabilities and going beyond the current status quo. So if I am working with someone, I will encourage them to excel and bring out the best of their abilities.
What are your past experiences in the MedTech industry?
My experience in the MedTech industry started over 20 years ago, so I have had the opportunity to be implicated in various management positions over the years. I was involved in building a company that was later sold to Boston Scientific and focused on implantable defibrillators and minimally invasive surgery. I was also a founding partner and Executive Sponsor of NayaMed during my time at Medtronic. The company developed and sold pacemakers and defibrillators online and without a sales force. My final corporate position in Medtronic was as Global VP Corporate Clinical.
How did you hear about Gondola?
I first met the co-founder and CEO of Gondola Medical Technologies, Francesco Cecchini, around five years ago at a TechTour event in Lausanne. We immediately had a good dialogue about Gondola and the therapy. Once I became responsible for the management of TechTour, our contact increased further.
What was your first reaction to Gondola AMPS Therapy?
My first reaction was a bit hesitant, to be honest. Coming from the MedTech environment and seeing such incredible clinical results before and after footage makes you wonder if this therapy is too good to be true. My concerns were quickly proven wrong, though, as I saw the company’s good management and the credible science behind the therapy.
How did you end up joining the Gondola’s board of Directors?
I was asked to join the board of directors at Gondola after working with the company as a consultant. This time allowed me to see how the company was being managed, the current financial situation, and the innovation potential. After getting to know more about Gondola Medical Technologies, I felt confident that the fit would be right.
What makes a good board member, and what role are you playing in the Gondola’s board of directors?
As a member of the board of directors, you have to either be part of the management of the company, provide financing or have valuable experience that can add to the discussions. For example, my experience and knowledge in and around the MedTech industry will prove very useful in defining the company’s strategy.
What do you imagine for Gondola’s future?
I see a bright future for Gondola Medical Technologies. First, we will need to reach a maximum of people in a specific therapeutic area, e.g., Parkinson’s disease. It will allow us to gain credibility with medical professionals and in the industry as a whole that we can then leverage to move on to further fields. By focusing on Parkinson’s disease, we can leverage the scientific evidence we already have and focus our efforts.